Sino Biological Inc
SZSE:301047
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
54.7
89.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sino Biological Inc
Sino Biological Inc
Accrued Liabilities
Sino Biological Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sino Biological Inc
SZSE:301047
|
Accrued Liabilities
¥55.4m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Accrued Liabilities
¥2.6B
|
CAGR 3-Years
49%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Accrued Liabilities
¥134.4m
|
CAGR 3-Years
57%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Accrued Liabilities
¥268.5m
|
CAGR 3-Years
37%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Accrued Liabilities
¥164.1m
|
CAGR 3-Years
50%
|
CAGR 5-Years
30%
|
CAGR 10-Years
19%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Accrued Liabilities
¥325.2m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
85%
|
CAGR 10-Years
60%
|
|
Sino Biological Inc
Glance View
Sino Biological Inc. provides protein, antibody and gene products. The company is headquartered in Beijing, Beijing and currently employs 495 full-time employees. The company went IPO on 2021-08-16. The firm's main business includes products such as recombinant proteins, antibodies, genes and culture media, as well as the development of recombinant proteins and antibodies, and biological analysis and testing services. The firm operates in the domestic market and overseas markets.
See Also
What is Sino Biological Inc's Accrued Liabilities?
Accrued Liabilities
55.4m
CNY
Based on the financial report for Dec 31, 2023, Sino Biological Inc's Accrued Liabilities amounts to 55.4m CNY.
What is Sino Biological Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
41%
Over the last year, the Accrued Liabilities growth was 22%. The average annual Accrued Liabilities growth rates for Sino Biological Inc have been -4% over the past three years , 41% over the past five years .
You don't have any saved screeners yet
